报告从政策环境、市场行情、厂商动态、科技研发、国际资讯、行业数据、分析评论等几个方面进行了分析评论。

报告从医药行业事件分析、竞争环境、竞争对手、行业数据等几个方面进行了分析评论。

报告从政策环境、市场行情、厂商动态、科技研发、国际资讯、行业数据、分析评论等几个方面进行了分析评论。

Asia-Pacific governments continued to focus on cutting the cost of pharmaceutical expenditure over the last six months, as part of an effort to cut overall healthcare costs. Healthcare expenditures rose along with per capita healthcare spending. China’s average per capita healthcare spending grew at higher rate than India and Australia. Leading Asian drugmakers posted a mixed bag of earnings. Takeda Pharmaceutical (TSE: 4502) recorded an increase in net sales, but a decline in net income. Dr. Reddy’s Laboratories (BSE:500124) experienced a large increase in net profit, meanwhile, Mitsubishi Tanabe Pharma (TSE:4508) posted modest sales growth and strong profitability with an increase in net income. Ten out of 11 leading Asian pharmaceutical companies posted positive gains in share prices during the reviewed period, with Ranbaxy’s stock price (BSE: 500359) rising the highest at 27.39%.

 

Diabetic neuropathy is a nerve disorder associated with diabetes. As a result of diabetic neuropathy, axonal damage decreases nerve action potential , thereby inhibiting neuronal signal transmission. Diabetic neuropathy is characterized by progressive damage to the myelin sheath, which slows down nerve conduction velocity. About 60-70 percent of diabetic patients develop neuropathy, with a considerable number of patients remaining undiagnosed during the initial years of progression. Hence, disease management should start with the initial diagnosis of diabetes. Diabetic neuropathy treatment involves lowering blood glucose levels (keeping it within the normal range) to prevent further nerve damage and treatment to provide symptomatic relief. Alternative therapies, which help in managing pain, such as biofeedback, meditation, acupuncture, or other relaxation techniques, can also be used to provide relief to patients.